FDA Clears First Treatment for CHAPLE Disease: Veopoz (pozelimab-bbfg) Injection
Veopoz (pozelimab-bbfg) injection, a complement inhibitor, has received FDA approval for managing CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, in patients aged one year and above. This marks the pioneering FDA-approved therapy for CHAPLE disease. Initially, Veopoz is administered intravenously, followed by weekly subcutaneous injections supervised by a healthcare professional. For comprehensive dosing instructions, refer to the prescribing information.